European Union - English - EMA (European Medicines Agency)

eli lilly and company limited - spinosad, milbemycin oxime - antiparasitic products, insecticides and repellents, endectocides - dogs - for the treatment and prevention of flea (ctenocephalides felis) infestations in dogs where one or more of the following indications are required concurrently: prevention of heartworm disease (l3, l4 dirofilaria immitis);prevention of angiostrongylosis by reducing the level of infection with immature adult (l5) angiostrongylus vasorum;treatment of gastrointestinal nematode infections caused by hookworm (l4, immature adult, l5) and adult ancylostoma caninum), roundworms (immature adult l5, and adult toxocara canis and adult toxascaris leonina) and whipworm (adult trichuris vulpis). 

European Union - English - EMA (European Medicines Agency)

eli lilly and company (ireland) limited - ixekizumab - psoriasis - immunosuppressants - plaque psoriasistaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritistaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (dmard) therapies.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - baricitinib - film coated tablets - baricitinib 4 mg - baricitinib - rheumatoid arthritisolumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. olumiant may be used as monotherapy or in combination with methotrexate.atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.alopecia areataolumiant is indicated for the treatment of severe alopecia areata in adult patients.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - galcanezumab - solution for injection - galcanezumab 120 mg / 1 ml - galcanezumab - emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - ramucirumab - concentrate for solution for infusion - ramucirumab 10 mg/ml - ramucirumab - gastric cancercyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.colorectal cancercyramza, in combination with folfiri (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.non-small cell lung cancercyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung adenocarcinoma with activating epidermal growth factor receptor (egfr) mutations.cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.hepatocellular carcinomacyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (afp) of ≥ 400 ng/ml and who have been previously treated with sorafenib.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - nortriptyline hydrochloride 11.4mg equivalent to to 10 mg nortriptyline base;   - tablet - 10 mg - active: nortriptyline hydrochloride 11.4mg equivalent to to 10 mg nortriptyline base   excipient: calcium phosphate glycerol hypromellose lactose monohydrate magnesium stearate starch

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - nortriptyline hydrochloride 28.5mg equivalent to 25 mg nortriptyline base;   - tablet - 25 mg - active: nortriptyline hydrochloride 28.5mg equivalent to 25 mg nortriptyline base   excipient: calcium phosphate glycerol hypromellose lactose monohydrate magnesium stearate starch sunset yellow fcf

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - nortriptyline hydrochloride 2.28 mg/ml equivalent to to 2 mg/ml nortriptyline - oral solution - 10 mg/5ml - active: nortriptyline hydrochloride 2.28 mg/ml equivalent to to 2 mg/ml nortriptyline excipient: benzoic acid ethanol cherry maraschino no. 38 purified water sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - aminophylline 130mg; amobarbital 25mg; ephedrine hydrochloride 25mg - capsule - 130mg/25mg/25mg - active: aminophylline 130mg amobarbital 25mg ephedrine hydrochloride 25mg

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - nizatidine - powder for injection - 50mg , 150mg , 300mg - active: nizatidine